Showing results (51-60 of 87) with videos related to
Sort By:
Pageof 9
Journal of Pediatric Hematology/Oncology|November 18, 2008
Rare occurrence of PHOX2b mutations in sporadic neuroblastomasAlexandre Serra, Beate Häberle, Inke R König, et al.Cancers|April 26, 2025
Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in HepatoblastomaLea Amelie Jung, Salih Demir, Alina Hotes, et al.Journal of Pediatric Gastroenterology and Nutrition|June 12, 2009
Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patientsMartin Lacher, Roland Kappler, Sebastian Schroepf, et al.Carcinogenesis|May 23, 2002
Unbalanced overexpression of the mutant allele in murine Patched mutantsJulia Calzada-Wack, Roland Kappler, Udo Schnitzbauer, et al.Journal of Cancer Research and Clinical Oncology|March 20, 2020
Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutationsIvonne Regel, Melanie Eichenmüller, Ujjwal Mukund Mahajan, et al.Cancers|August 14, 2025
Does Chemotherapy Have an Effect on the Treatment Success of Children and Adolescents with Unresectable Hepatocellular Carcinoma? Findings from the German Liver Tumour RegistryMark Rassner, Beate Häberle, Rebecca Maxwell, et al.Molecular Cancer|March 10, 2012
IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumorsIvonne Regel, Melanie Eichenmüller, Saskia Joppien, et al.Developmental Biology|April 28, 2004
An enhancer directs differential expression of the linked Mrf4 and Myf5 myogenic regulatory genes in the mouseTed Hung-Tse Chang, Michael Primig, Juliette Hadchouel, et al.Cancers|January 27, 2021
Erratum: Wagner, A.E., et al. SP8 Promotes an Aggressive Phenotype in Hepatoblastoma via FGF8 Activation. <i>Cancers</i> 2020, <i>12</i>, 2294Alexandra Elisabeth Wagner, Thomas Schwarzmayr, Beate Häberle, et al.International Journal of Molecular Sciences|June 26, 2026
Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for HepatoblastomaSalih Demir, Marie Friederike Bentrop, Alina Hotes, et al.Pageof 9